E-News Newsletter - October 2020
Alliance at ASCO

2020 Virtual ASCO MEETING

The Alliance for Clinical Trials in Oncology presented more than 20 studies, sharing the latest finding on breast cancer, head and neck cancer, lung cancer, GI and GU cancers, along with cancer control research, at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO), which convened virtually May 29-31. The ASCO meeting brought together oncology professionals from around the world under the meeting theme: "Unite and Conquer: Accelerating Progress Together." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, were highlighted. 
Alliance investigators presented these studies:

Breast Cancer - Local/Regional/Adjuvant      
A011106 :: ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106
Lead author: Cynthia X. Ma | Abstract: 504 | Clinical trial information: NCT01953588
N9831 ::  Value of CTS5 for Late Relapse Risk Assessment in Patients with Early Stage HER2+ Breast Cancer in the NCCTG N9831 (Alliance) Trial
Lead author: Tanmayi Pai
Abstract/Poster: 529 / 21    
Clinical trial information: NCT00005970
Cancer Prevention, Risk Reduction, and Genetics   
C50303 :: Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy in patients with diffuse large B-cell lymphoma on Alliance/CALGB 50303
Lead author: Daniel L. Hertz | Abstract: E13535
Central Nervous System
A071401 ::  Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations
Lead author: Priscilla K. Brastianos | Abstract: 2502 | Clinical trial information: NCT02523014
A071701 ::  Alliance A071701: Genomically guided treatment trial in brain metastases
Lead author: Priscilla Brastianos | Abstract/Poster: TPS2573 / 64 | Clinical trial information: NCT03994796
Developmental Therapeutics - Immunotherapy       
A151804, 9767 ::  Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
Lead author: David Kozono | Abstract/Poster: TPS3154 / 218 | Clinical trial information: NCT04242095
Gastrointestinal Cancer - Colorectal and Anal         
C80405 ::  Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)
Lead author: Francesca Battaglin | Abstract/Poster: 4086 / 78 | Clinical trial information: NCT00265850
C80405, N9741 :: Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively
Lead author: Midhun Malla | Abstract: E16076 | Clinical trial information: NCT00003594 NCT00265850

C80702 :: Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702
Lead author: Jeffrey A. Meyerhardt | Abstract: 4003 | Clinical trial information: NCT01150045
N0147 :: Tumor-infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147) [Alliance]
Lead author: D. Sha | Abstract/Poster: 4065 / 57
C80702  ::  Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration
Lead author: Alberto F. Sobrero | Abstract: 4004 | Clinical trial information: NCT01150045
Genitourinary Cancer - Kidney and Bladder
A031704 ::  PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
Lead author: Tian Zhang | Abstract/Poster: TPS5100 / 169 | Clinical trial information: NCT03793166
Health Services Research and Quality Improvement        
AFT-39  ::  Nurse, oncologist, and patient impressions of electronic symptom monitoring via patient-reported outcomes in community oncology practices: Qualitative results from the U.S. national PRO-TECT trial
Lead author: Ethan Basch | Abstract/Poster: 7044 / 316 | Clinical trial information: NCT03249090
A151925, A091105, COMET-2  ::  Composite grading algorithm for National Cancer Institute's PRO-CTCAE
Lead author: Amylou C. Dueck | Abstract/Poster: 7018 / 290
Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia           
C51101 ::  Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101
Lead author: Tracy Batchelor | Abstract/Poster: 8042 / 375 | Clinical trial information: NCT01511562
A041202  ::  Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202
Lead author: Amy S. Ruppert | Abstract: E20004 | Clinical trial information: NCT01886872
A051103, C50701, C50801, C50901, S0016, S0816  ::  Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials
Lead author: Sarah C. Rutherford | Abstract/Poster: 8038 / 371          
Clinical trial information:  NCT00553501 NCT01145495 NCT01190449 NCT01286272 NCT01829568 NCT00822120 NCT00770224

Non-Small Cell Local/Regional/Small Cell/Other Thoracic Cancers       
AFT-16   ::   AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC
Lead author: Helen J. Ross | Abstract/Poster: 9045 / 238 | Clinical trial information: NCT03102242
A081105, A151216, A081801  ::  ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high risk resected NSCLC (Alliance)
Lead author: Jacob Sands | Abstract/Poster: TPS9077 / 270 | Clinical trial information: NCT02194738
A091401  ::   A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts
Lead author: James Chen | Abstract/Poster: 11511 /399 | Clinical trial information: NCT02500797

A091304  ::  A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304)
Lead author: Matthew Ingham | Abstract/Poster: 11562 / 450 | Clinical trial information: NCT02601209
Symptoms and Survivorship     
Pilot  ::  A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome
Lead author: Zoneddy Dayao | Abstract: E24115 | Clinical trial information: NCT01821833     
Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer. (NCT03396510)
Lead author: Ryan D. Nipp | Abstract/Poster: 12014 / 302 | Clinical trial information: NCT03396510
A221101  ::   A phase III randomized, double-blind placebo-controlled study of armodafinil (nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma (Alliance A221101)
Lead author: Alyx B. Porter | Abstract: 12007 | Clinical trial information: NCT01781468
A191402CD  ::  Decision aids for localized prostate cancer: Outcomes from an Alliance Research Base Cancer Care Delivery Research (CCDR) protocol - A191402CD
Lead author: Jon Tilburt | Abstract: e24176 | Clinical trial information: NCT03103321


For other articles in this issue of Alliance E-News, see below.